What is HC Wainwright’s Estimate for ARQT FY2027 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Stock analysts at HC Wainwright raised their FY2027 EPS estimates for shares of Arcutis Biotherapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $1.12 per share for the year, up from their previous estimate of $0.94. HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2028 earnings at $1.82 EPS.

ARQT has been the topic of a number of other reports. Mizuho boosted their target price on shares of Arcutis Biotherapeutics from $20.00 to $21.00 and gave the stock an “outperform” rating in a research report on Wednesday. The Goldman Sachs Group boosted their price objective on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $20.00 price objective on shares of Arcutis Biotherapeutics in a research report on Wednesday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Arcutis Biotherapeutics in a research report on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Arcutis Biotherapeutics Stock Performance

Arcutis Biotherapeutics stock opened at $13.69 on Friday. The firm has a market capitalization of $1.60 billion, a PE ratio of -7.65 and a beta of 1.29. Arcutis Biotherapeutics has a one year low of $6.99 and a one year high of $16.20. The stock’s 50 day moving average price is $13.56 and its 200 day moving average price is $11.43. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.38 and a current ratio of 2.46.

Arcutis Biotherapeutics (NASDAQ:ARQT) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.19. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The company had revenue of $71.36 million for the quarter, compared to analysts’ expectations of $60.52 million.

Institutional Trading of Arcutis Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in shares of Arcutis Biotherapeutics during the 4th quarter valued at about $34,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Arcutis Biotherapeutics by 1.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 280,100 shares of the company’s stock valued at $3,902,000 after acquiring an additional 3,409 shares during the period. Voloridge Investment Management LLC grew its holdings in shares of Arcutis Biotherapeutics by 126.5% during the fourth quarter. Voloridge Investment Management LLC now owns 290,938 shares of the company’s stock valued at $4,053,000 after purchasing an additional 162,495 shares during the last quarter. Squarepoint Ops LLC raised its position in shares of Arcutis Biotherapeutics by 67.2% during the 4th quarter. Squarepoint Ops LLC now owns 121,392 shares of the company’s stock worth $1,691,000 after purchasing an additional 48,769 shares during the period. Finally, Suvretta Capital Management LLC lifted its holdings in shares of Arcutis Biotherapeutics by 6.3% in the 4th quarter. Suvretta Capital Management LLC now owns 11,399,138 shares of the company’s stock worth $158,790,000 after purchasing an additional 677,627 shares during the last quarter.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Franklin Watanabe sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $15.17, for a total transaction of $227,550.00. Following the sale, the insider now owns 823,430 shares in the company, valued at $12,491,433.10. This represents a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.67, for a total value of $146,700.00. Following the completion of the transaction, the director now owns 151,944 shares of the company’s stock, valued at approximately $2,229,018.48. The trade was a 6.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 55,029 shares of company stock worth $756,017 in the last ninety days. 9.50% of the stock is owned by insiders.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.